37 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
in $5.0 million in gross proceeds.
R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
and warrants, raising approximately $5.0 million in gross proceeds.
R&D Expenses: Research and development expenses for the third quarter of 2023 were
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
, a decrease of $5.1 million.
R&D Expenses: Research and development expenses for the second quarter of 2023 were $3.0 million, compared to $0.2
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
12 May 23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:35am
, compared to $6.7 million at December 31, 2022, an increase of $1.5 million.
R&D Expenses: Research and development expenses for the first quarter … of 2023 were $1.2 million, compared to $1.8 million for the first quarter of 2022.
R&D – Licenses Acquired Expenses: Research and development – licenses
8-K
EX-99.1
s01bpa2djvtyeg
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
EX-99.1
1ai250enrl8r0xrw0
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
424B4
xl5e5
11 Oct 22
Prospectus supplement with pricing info
8:27am
8-K
EX-99.1
29ifq3o
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
1pqe46qjw sljbpn
11 May 20
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
9:00am